Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Abstract Axial Spondyloarthritis (AxSpA) is a chronic illness with limited treatment options. The role of Janus kinase (JAK) inhibition as a therapeutic option has increasingly become a focus of research in recent years as they have brought a new mode of action to the clinical armamentarium. This review will assess the efficacy and safety profile of these drugs in AxSpA. The current phase 2 and 3 clinical trial data will be summarized, across tofacitinib, upadacitinib and filgotinib. Moreover, the safety profiles of these drugs, in the context of emerging safety signals such as during ORAL surveillance study, will be reviewed. In summary, JAK-inhibitors offer a novel therapeutic target for AxSpA and appear to address some of the unmet needs for patients who have either failed to respond to current treatment options or in whom they are contraindicated. There is a relative lack of evidence in non-radiographic AxSpA, and longer-term trials are needed to establish true efficacy and safety profile in radiographic AxSpA.

Original publication

DOI

10.1093/rap/rkae141

Type

Journal article

Journal

Rheumatology Advances in Practice

Publisher

Oxford University Press (OUP)

Publication Date

07/11/2024